Abstract:Proteins involved in immune checkpoint pathways, such as CTLA4, PD-1, and PD-L1, have become important targets for cancer immunotherapy; however, the development of small molecule drugs targeting these pathways has proven difficult due to the nature of their protein-protein interfaces. Here, using a hierarchy of computational techniques, we designed a cyclic peptide that binds CTLA4 and follow this with experimental verification of binding and biological activity, using bio-layer interferometry, cell culture, and a lung cancer mouse model in immunocompetent mice. Beginning from a template excised from the x-ray structure of the CTLA4:B7-2 complex, we generate several peptide sequences using Rosetta, a protein modelling program. These peptides are cyclized head-to-tail to improve structural and proteolytic stability and screened using molecular dynamics simulation and MM-GBSA calculation. The standard binding free energies for shortlisted peptides are then calculated in explicit-solvent simulation using a rigorous multistep Binding Free Energy Estimator (BFEE). The most promising peptide, cyc-EIDTVLTPTGWVAKRYS (hereafter CTLA4-ip), yields the standard free energy -6.6 ± 3.5 kcal/mol, which corresponds to a dissociation constant of 15 μmol/L. The binding affinity of this peptide for CTLA4 is measured experimentally (31 ± 4 μmol/L) using bio-layer interferometry. Pharmacokinetics of CTLA4-ip in a cell culture with Lewis lung carcinoma (LLC) cells and in mice revealed that this peptide is significantly more stable in both cell culture and in mice as compared to a control non-cyclic scrambled-sequence. Treatment with CTLA4-ip inhibited cancer cell growth in a co-culture of LLC cells and LLC cell-antigen primed murine T cells. Intraperitoneal administration of the CTLA4-ip (10mg/kg/day, every other day totaling 4 doses) markedly inhibited lung tumor growth in mice with an orthotropic LLC allograft model. Efficacy of the tumor growth inhibition by the CTLA4-ip was similar to that by an anti-PD-L1 antibody (10mg/kg/day, every two days totaling 3 doses). These results strongly suggest that this novel CTLA4-ip works as an immune checkpoint inhibitor to CTLA4 and is usable for lung cancer treatment. This research was supported by Kansas State University Johnson Cancer Research center (MT), Midwest Biomedical Accelerator Consortium (MT, JC), National Cancer Institute MT, JC) and the National Science Foundation (JC). Citation Format: Ravindra Thakkar, Deepa Upreti, Susumu Ishiguro, Geraldine Magnin, Keshari Sudasinghe, Anabelle Hall, Sarah DeVader, Masaaki Tamura, Jeffrey Comer. Computational design of a cyclic peptide that inhibits the CTLA4 in T cells and the growth of lung carcinoma in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1352.

Design and Biophysical Characterization of Second-Generation Cyclic Peptide LAG-3 Inhibitors for Cancer Immunotherapy

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction

Abstract 1352: Computational design of a cyclic peptide that inhibits the CTLA4 in T cells and the growth of lung carcinoma in mice

Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines

Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy

Computational design of a cyclic peptide that inhibits the CTLA4 immune checkpoint

Bioactive Peptide Design Based on Protein Surface Epitopes: A CYCLIC HEPTAPEPTIDE MIMICS CD4 DOMAIN 1 CC′ LOOP AND INHIBITS CD4 BIOLOGICAL FUNCTION

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy

Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy

Design and Immunological Evaluation of a Hybrid Peptide As a Potent TLR2 Agonist by Structure-Based Virtual Screening.

In Silico Design of Peptide Inhibitors Targeting HER2 for Lung Cancer Therapy

Crystal structure of the human LAG-3–HLA-DR1–peptide complex

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity

Computational design of cyclic peptides to inhibit protein-peptide interactions

Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor As Immune Modulator for Cancer Therapy

Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitors

A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells